All Curated Mutation Sites in HBV

The Virus Mutation(VM) module provides researchers the annotations of reported pathogenic mutations in HBV related to human diseases. The curated VM information includes mutation site, mutation level, virus gene/protein/region, virus-associated disease, genotype/subtype, literature evidence, etc.

Browse Data by Virus Gene/Protein/Region, Disease OR Description

*Please select one option you are interested in, the page will be automatically redirected.

Virus Gene/Protein

Disease

Description

For highly variable viruses (e.g., HBV, HIV, SARS-CoV-2), ViMIC defaults to displaying mutations in a specific region. Click the green button to search for other regions, or click "Show All" to view all mutations (loading speed may be affected by network conditions).

Show All

BCP

Core Promoter

Core Upstream Regulatory Sequence

Keyword: Hepatitis B, Chronic-19280622

ID	PMID	Mutation	Gene/Protein/Region	Encoding Gene/Protein	Disease	Description	Detail
1	19280622	L180M	RT	P	Hepatitis B, Chronic	D G C L	View
2	19280622	M204I	RT	P	Hepatitis B, Chronic	D G C L	View
3	19280622	M204V	RT	P	Hepatitis B, Chronic	D G C L	View
4	19280622	M250V			Hepatitis B, Chronic	D G C L	View
5	19280622	S202G			Hepatitis B, Chronic	D G C L	View
6	19280622	T184A			Hepatitis B, Chronic	D G C L	View
7	19280622	T184C			Hepatitis B, Chronic	D G C L	View
8	19280622	T184F			Hepatitis B, Chronic	D G C L	View
9	19280622	T184G			Hepatitis B, Chronic	D G C L	View
10	19280622	T184L			Hepatitis B, Chronic	D G C L	View
11	19280622	T184M			Hepatitis B, Chronic	D G C L	View
12	19280622	F88Y	RT	P	Hepatitis B, Chronic	G C L	View
13	19280622	A181C	RT	P	Hepatitis B, Chronic	D G C L	View
14	19280622	A181G	RT	P	Hepatitis B, Chronic	D G C L	View
15	19280622	A181S	RT	P	Hepatitis B, Chronic	D G C L	View
16	19280622	A181T	RT	P	Hepatitis B, Chronic	D G C L	View
17	19280622	A181V	RT	P	Hepatitis B, Chronic	D G C L	View

Contents
Description

The table shows all curated mutation sites of HBV in each literature

Table Description Column Note

D
The study mentioned a certain treatment method, such as drug resistance caused by mutations.

G
The study mentioned the virus genotype/subtype information.

R
The study mentioned the reference sequence used for comparison, or the original strain of the virus used for site-directed mutagenesis.

S
The study provided sequence information or accession numbers.

L
The study provided the geographic region/country of data origin.

C
The study provided clinical baseline information.

I
The study involved information related to immune.

T
The study involved host target genes.